Nurix Therapeutics to Host R&D Day on May 26, 2022

Event will include guest speaker, Dr. Anthony Mato, Director of the CLL Program at Memorial Sloan Kettering Cancer Center

San Francisco, California, UNITED STATES

SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced it will host a research & development (R&D) day for analysts and investors that will be held on Thursday, May 26, 2022 from 8:00 a.m. to 11:00 a.m. ET in New York City.

The R&D Day will feature a presentation by guest speaker, Anthony Mato, M.D., MSCE, director of the chronic lymphocytic leukemia (CLL) Program at Memorial Sloan Kettering Cancer Center, who will provide a perspective on the clinical experience and unmet need in hematologic malignancies.

The event will include presentations from Nurix’s management team, who will provide a comprehensive update on Nurix’s four clinical programs, DELigase® discovery platform and future development plans.

A live webcast, as well as a replay, will be available in the Investors section of the Nurix website under Events and Presentations.

About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit


Elizabeth Wolffe, Ph.D.Brett Whelan
Wheelhouse Life Science AdvisorsLifeSci Communications